Alguien sigue a BIOF o PEIX? PEIX presentó balance hoy... -8% ahora...
PEIX: The company lost $2.4 million in the third quarter, compared to a profit of $8.2 million in the same quarter last year. The loss was slightly narrower than the $2.6 million posted in the second quarter.
BIOF presenta el balance al cierre de hoy...
Papeles volátiles (Small caps)
Re: Papeles volátiles (Small caps)
Perdòn eh,pero SYNC no saliò al mercado en estos valores ?
Que va a ir a cerrar ahora el gap que dejò entre 0 y 4,60
Que va a ir a cerrar ahora el gap que dejò entre 0 y 4,60
Re: Papeles volátiles (Small caps)
gahvet escribió:Para Sergei
Disculpen los demas por el off the topic
Sergei, como estas !!. Vi en otro topic, que trabajas en un laboratorio veterinario.
Si te interesa yo tengo un pequeño laboratorio veterinario totalmente habilitado, que recién está empezando a operar.
Estoy en un punto en que el cuql em vien bien hacer algun tipo de alinzas con alguien que tenga conocimientosny contactos en el mercado.
No sé si te interesa, quizás haya para hacer algún negocio. Si te parece, no sé cómo se hará para pasarnos los mail o teléfonos de contacto, así te paso la propuesta y te comento todo al respecto.
Saludos,
solicitale mi mail a JIR
Guillermo.
Re: Papeles volátiles (Small caps)
Para Sergei
Disculpen los demas por el off the topic
Sergei, como estas !!. Vi en otro topic, que trabajas en un laboratorio veterinario.
Si te interesa yo tengo un pequeño laboratorio veterinario totalmente habilitado, que recién está empezando a operar.
Estoy en un punto en que el cuql em vien bien hacer algun tipo de alinzas con alguien que tenga conocimientosny contactos en el mercado.
No sé si te interesa, quizás haya para hacer algún negocio. Si te parece, no sé cómo se hará para pasarnos los mail o teléfonos de contacto, así te paso la propuesta y te comento todo al respecto.
Saludos,
Guillermo.
Disculpen los demas por el off the topic
Sergei, como estas !!. Vi en otro topic, que trabajas en un laboratorio veterinario.
Si te interesa yo tengo un pequeño laboratorio veterinario totalmente habilitado, que recién está empezando a operar.
Estoy en un punto en que el cuql em vien bien hacer algun tipo de alinzas con alguien que tenga conocimientosny contactos en el mercado.
No sé si te interesa, quizás haya para hacer algún negocio. Si te parece, no sé cómo se hará para pasarnos los mail o teléfonos de contacto, así te paso la propuesta y te comento todo al respecto.
Saludos,
Guillermo.
Re: Papeles volátiles (Small caps)
Buen dia a todos, hoy el DOW NO ACOMPAÑA 
e bue 
e bue Re: Papeles volátiles (Small caps)
AONE tiene la Q........ 
Re: Papeles volátiles (Small caps)
dragon escribió:en AIQ, la ves que apunta a la sma200 weekly ?
yo creo que el primer objetivo puede ser los 2.40 y luego 3.30 rompio una resistencia importante con un volumen inusual para la accion, saludos sergi , no toy en esa.
mmmmm PEIX QUE JODA[/quote]
por el dato de un amigo con peix me mandé el mejor trade de mi vida, que recuerdo
Re: Papeles volátiles (Small caps)
OK dragón! No hay drama, me pareció importante publicarlo nomás... 
Re: Papeles volátiles (Small caps)
Pocoyo escribió:PPHM
Lieff Cabraser Reminds Peregrine Pharmaceuticals, Inc. Investors of Upcoming Deadline in Class Action Lawsuits
9:00a ET November 6, 2012 (Business Wire) Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the November 27, 2012 deadline to move for appointment as lead plaintiff in the securities class litigation against Peregrine Pharmaceuticals, Inc. ("Peregrine" or the "Company") (NASDAQ:PPHM), brought on behalf of all persons who purchased or otherwise acquired the securities of Peregrine between July 16, 2012 and September 26, 2012, inclusive (the "Class Period").
If you purchased or otherwise acquired Peregrine securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than November 27, 2012. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.
Peregrine shareholders who wish to learn more about the action and how to seek appointment as lead plaintiff should click here or contact Sharon Lee of Lieff Cabraser toll-free at 1 (800) 541-7358.
Peregrine is a biopharmaceutical company focused on the research, development and commercialization of therapeutics for cancer and viral infections.
The actions allege that during the Class Period, defendants issued materially false and misleading statements regarding the effectiveness of one of its key products, bavituxmab, an experimental drug for the treatment of non-small cell lung cancer. Specifically, defendants failed to disclose that there were major discrepancies in the results of the Company's Phase II bavituxmab trial involving patients with second line non-small cell lung cancer, and that the results Peregrine previously disclosed were not reliable.
On September 24, 2012, Peregrine disclosed that it had discovered "major discrepancies" in the treatment group in the Phase II trial and cautioned investors that they should not rely on previously reported clinical data from the Phase II trial. On this news, Peregrine shares fell $4.23 per share, or over 78%, to close at $1.16 per share.
On September 26, 2012, after the market closed, Peregrine disclosed that it had received a notice of default from one of its lenders which deemed the Company's disclosure on September 24, 2012 concerning the Phase II trial results to be a material adverse change under the terms of the loan agreement and, as a result, the lender accelerated the repayment of the loan and demanded repayment in full for the outstanding loan amount. On this news, Peregrine shares fell another $0.55 per share, or over 33%, to close at $1.11 per share on September 27, 2012.
About Lieff Cabraser
Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.
Since 2003, the National Law Journal has selected Lieff Cabraser as one of the top plaintiffs' law firms in the nation. Lieff Cabraser is one of only two plaintiffs' law firms in the United States to receive this honor for the last ten consecutive years.
For more information about Lieff Cabraser and the firm's representation of investors, please visit http://www.lieffcabraser.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE: Lieff Cabraser Heimann & Bernstein, LLP
Lieff Cabraser Heimann & Bernstein, LLP
Sharon M. Lee, 800-541-7358
no me caracterizo por ir long , solo un rebote y rajoooooooooooooo buena la info
Re: Papeles volátiles (Small caps)
en AIQ, la ves que apunta a la sma200 weekly ?[/quote]
yo creo que el primer objetivo puede ser los 2.40 y luego 3.30 rompio una resistencia importante con un volumen inusual para la accion, saludos sergi , no toy en esa.
mmmmm PEIX QUE JODA
yo creo que el primer objetivo puede ser los 2.40 y luego 3.30 rompio una resistencia importante con un volumen inusual para la accion, saludos sergi , no toy en esa.
mmmmm PEIX QUE JODA
Re: Papeles volátiles (Small caps)
PPHM
Lieff Cabraser Reminds Peregrine Pharmaceuticals, Inc. Investors of Upcoming Deadline in Class Action Lawsuits
9:00a ET November 6, 2012 (Business Wire) Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the November 27, 2012 deadline to move for appointment as lead plaintiff in the securities class litigation against Peregrine Pharmaceuticals, Inc. ("Peregrine" or the "Company") (NASDAQ:PPHM), brought on behalf of all persons who purchased or otherwise acquired the securities of Peregrine between July 16, 2012 and September 26, 2012, inclusive (the "Class Period").
If you purchased or otherwise acquired Peregrine securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than November 27, 2012. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.
Peregrine shareholders who wish to learn more about the action and how to seek appointment as lead plaintiff should click here or contact Sharon Lee of Lieff Cabraser toll-free at 1 (800) 541-7358.
Peregrine is a biopharmaceutical company focused on the research, development and commercialization of therapeutics for cancer and viral infections.
The actions allege that during the Class Period, defendants issued materially false and misleading statements regarding the effectiveness of one of its key products, bavituxmab, an experimental drug for the treatment of non-small cell lung cancer. Specifically, defendants failed to disclose that there were major discrepancies in the results of the Company's Phase II bavituxmab trial involving patients with second line non-small cell lung cancer, and that the results Peregrine previously disclosed were not reliable.
On September 24, 2012, Peregrine disclosed that it had discovered "major discrepancies" in the treatment group in the Phase II trial and cautioned investors that they should not rely on previously reported clinical data from the Phase II trial. On this news, Peregrine shares fell $4.23 per share, or over 78%, to close at $1.16 per share.
On September 26, 2012, after the market closed, Peregrine disclosed that it had received a notice of default from one of its lenders which deemed the Company's disclosure on September 24, 2012 concerning the Phase II trial results to be a material adverse change under the terms of the loan agreement and, as a result, the lender accelerated the repayment of the loan and demanded repayment in full for the outstanding loan amount. On this news, Peregrine shares fell another $0.55 per share, or over 33%, to close at $1.11 per share on September 27, 2012.
About Lieff Cabraser
Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.
Since 2003, the National Law Journal has selected Lieff Cabraser as one of the top plaintiffs' law firms in the nation. Lieff Cabraser is one of only two plaintiffs' law firms in the United States to receive this honor for the last ten consecutive years.
For more information about Lieff Cabraser and the firm's representation of investors, please visit http://www.lieffcabraser.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE: Lieff Cabraser Heimann & Bernstein, LLP
Lieff Cabraser Heimann & Bernstein, LLP
Sharon M. Lee, 800-541-7358
Lieff Cabraser Reminds Peregrine Pharmaceuticals, Inc. Investors of Upcoming Deadline in Class Action Lawsuits
9:00a ET November 6, 2012 (Business Wire) Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the November 27, 2012 deadline to move for appointment as lead plaintiff in the securities class litigation against Peregrine Pharmaceuticals, Inc. ("Peregrine" or the "Company") (NASDAQ:PPHM), brought on behalf of all persons who purchased or otherwise acquired the securities of Peregrine between July 16, 2012 and September 26, 2012, inclusive (the "Class Period").
If you purchased or otherwise acquired Peregrine securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than November 27, 2012. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.
Peregrine shareholders who wish to learn more about the action and how to seek appointment as lead plaintiff should click here or contact Sharon Lee of Lieff Cabraser toll-free at 1 (800) 541-7358.
Peregrine is a biopharmaceutical company focused on the research, development and commercialization of therapeutics for cancer and viral infections.
The actions allege that during the Class Period, defendants issued materially false and misleading statements regarding the effectiveness of one of its key products, bavituxmab, an experimental drug for the treatment of non-small cell lung cancer. Specifically, defendants failed to disclose that there were major discrepancies in the results of the Company's Phase II bavituxmab trial involving patients with second line non-small cell lung cancer, and that the results Peregrine previously disclosed were not reliable.
On September 24, 2012, Peregrine disclosed that it had discovered "major discrepancies" in the treatment group in the Phase II trial and cautioned investors that they should not rely on previously reported clinical data from the Phase II trial. On this news, Peregrine shares fell $4.23 per share, or over 78%, to close at $1.16 per share.
On September 26, 2012, after the market closed, Peregrine disclosed that it had received a notice of default from one of its lenders which deemed the Company's disclosure on September 24, 2012 concerning the Phase II trial results to be a material adverse change under the terms of the loan agreement and, as a result, the lender accelerated the repayment of the loan and demanded repayment in full for the outstanding loan amount. On this news, Peregrine shares fell another $0.55 per share, or over 33%, to close at $1.11 per share on September 27, 2012.
About Lieff Cabraser
Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.
Since 2003, the National Law Journal has selected Lieff Cabraser as one of the top plaintiffs' law firms in the nation. Lieff Cabraser is one of only two plaintiffs' law firms in the United States to receive this honor for the last ten consecutive years.
For more information about Lieff Cabraser and the firm's representation of investors, please visit http://www.lieffcabraser.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE: Lieff Cabraser Heimann & Bernstein, LLP
Lieff Cabraser Heimann & Bernstein, LLP
Sharon M. Lee, 800-541-7358
Re: Papeles volátiles (Small caps)
porsupuesto Niko que estoy en PPHM desde los 0.72 no las largo hasta 1.20 o 1.40, lo unico que tengo es
GURE
PEIX
PPHM
esta que entraba en AIQ pero me tento mas PEIX
GURE
PEIX
PPHM
esta que entraba en AIQ pero me tento mas PEIX
¿Quién está conectado?
Usuarios navegando por este Foro: abeja_fenix, Ahrefs [Bot], Amazon [Bot], Aprendiz70, BACK UP, Baidu [Spider], bariloche, Bing [Bot], Blabla2222, cabeza70, Capitan, Charly-N, chewbaca, danyf1, davinci, debenede, deportado, DULIATICO, el indio, EL REY, elcipayo16, ElCrotodelNovato, ELViS_PRESLEY, Fabian66, frankcores, Funebrero, Gon, Google [Bot], Guardameta, Gusbull, j5orge, jose enrique, ljoeo, luis, MatiasMonte, Matu84, Morlaco, Mustayan, napolitano, notescribo, PiraniaPersonal, Pizza_birra_bolsa, pollomoney, redtoro, Robespierre, Scrat, sebara, Semrush [Bot], silverado, Sir, SoloSeQueNoSe, te voy dando, Vinci, zippo y 1127 invitados